House Democrats launch drug pricing probe into a dozen major health-care companies  01/14/2019 17:09:18  2  Berkeley Lovelace Jr.
Rep. Elijah Cummings, D-Md.
Bill Clark | CQ Roll Call | Getty Images
Rep. Elijah Cummings, D-Md.

The House Oversight Committee is investigating the actions of a dozen pharmaceutical companies in raising prescription drug prices in the U.S., the panel announced Monday.

Chairman Elijah Cummings, D-Md., sent letters to AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals seeking detailed information and documents about the companies' pricing practices.

"For years, drug companies have been aggressively increasing prices on existing drugs and setting higher launch prices for new drugs while recording windfall profits," Cummings said in a statement. "The goals of this investigation are to determine why drug companies are increasing prices so dramatically, how drug companies are using the proceeds, and what steps can be taken to reduce prescription drug prices."

Democrats, who regained control of the House this month, listed lowering prescription drug costs as one of their top priorities. Cummings, along with Sen. Bernie Sanders and Rep. Ro Khanna, D-Ca., introduced three bills last week aimed at lowering drug costs.

Spending on prescription drugs in the U.S. increased 0.4 percent in 2017 to $333.4 billion, according to the latest data from the Centers for Medicare and Medicaid Services. Lawmakers have largely been focusing on the pharmaceutical industry, which sells drugs at higher prices in the U.S. than abroad.

« Go back